To the Editor Dexmedetomidine, a drug with novel mechanisms of action, is used for treatment of delirium in critically ill patients in intensive care units. A recent study investigating sublingual dexmedetomidine efficacy found that this drug reduced mild to moderate agitation in patients with bipolar disorder. We have 2 concerns about interpreting the results of this study.
